TC Biopharm (Holdings) Plc (NASDAQ:TCBP) Short Interest Up 65.4% in December

TC Biopharm (Holdings) Plc (NASDAQ:TCBP) was the recipient of a large increase in short interest in December. As of December 15th, there was short interest totalling 31,600 shares, an increase of 65.4% from the November 30th total of 19,100 shares. Based on an average daily trading volume, of 1,650,000 shares, the days-to-cover ratio is presently 0.0 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright lowered their price objective on TC Biopharm from $7.00 to $3.00 and set a “buy” rating for the company in a research report on Friday, December 6th.

TC Biopharm Stock Performance

TCBP remained flat at $0.71 during mid-day trading on Friday. 676,019 shares of the company’s stock traded hands, compared to its average volume of 623,716. The business’s fifty day simple moving average is $0.94 and its two-hundred day simple moving average is $4.67. TC Biopharm has a 12 month low of $0.44 and a 12 month high of $41.50. The company has a debt-to-equity ratio of 0.67, a quick ratio of 0.88 and a current ratio of 1.12.

About TC Biopharm

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers.